Sunesis Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Covering Vosaroxin Compositions

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 12/982,785 claiming certain compositions related to Sunesis' lead drug candidate, vosaroxin.

The patent will grant Sunesis exclusive rights to certain Active Pharmaceutical Ingredient compositions of vosaroxin, as well as the final product related to such compositions, and provides patent exclusivity to mid 2030 in the United States. A family of corresponding patent applications are pending in the U.S. and internationally.